COO Cooper Companies Inc.

CooperCompanies Publishes 2022 Environmental, Social, and Governance Report, Shares Progress on Creating Value for Stakeholders

CooperCompanies Publishes 2022 Environmental, Social, and Governance Report, Shares Progress on Creating Value for Stakeholders

SAN RAMON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today released its . It highlights the company's progress on social and environmental issues most important to its businesses and stakeholders, including employees, shareholders, customers, and global communities.

In 2022, CooperCompanies manufactured a record number of products while reducing greenhouse gas (GHG) emissions by more than 7%. A big contributor to this success was the start of the operation of a combined heat and power (CHP) facility in Puerto Rico. The company expects the CHP system to help significantly reduce its carbon footprint in the coming years.

"At CooperCompanies, we are committed to working diligently to positively impact the world around us," said Al White, President and CEO of CooperCompanies. "In 2022, we continued making great progress and we're proud of the success we've had, and the direction in which we're moving. Conducting business in a socially and environmentally responsible manner is important to our long-term business success, and to the future of our planet."

The 2022 ESG Report includes expanded and updated ESG performance data and provides stories across the company's ESG pillars: People, Planet, and Partnerships. The report is aligned with the Sustainability Accounting Standards Board (SASB) Standards, a leading framework that identifies important ESG issues most relevant to investors.

Read more in the Cooper 2022 ESG Report: .

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 14,000 with products sold in over 100 countries. For more information, please visit .

Forward Looking Statements

This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including all statements regarding planned ESG programs and goals, the anticipated impact of ESG activities, and product and technology plans, are forward-looking. To identify these statements, look for words like “believes,” “outlook,” “probable,” “expects,” “may,” “will,” “should,” “could,” “seeks,” “intends,” “plans,” “estimates,” or “anticipates” and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data, or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political, and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; the impact of Russia's invasion of Ukraine and the global response to this invasion on the global economy, European economy, financial markets, energy markets, currency rates, and our ability to supply product to, or through, affected countries; compliance costs and potential liability in connection with U.S., and foreign laws and healthcare regulations pertaining to privacy and security of personal information; a major disruption in the operations of our manufacturing, accounting, and financial reporting, research, and development, distribution facilities or raw material supply chain; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations, and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the healthcare industry; new competitors, product innovations or technologies; reduced sales, loss of customers, and costs and expenses related to product recalls and warning letters; failure to receive, or delays in receiving, regulatory approvals or certifications for products; risks related to ESG issues, including those related to climate change and sustainability; and other events described in our Securities and Exchange Commission filings, including the “Business,” “Risk Factors,” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in the our Annual Report on Form 10-K for the fiscal year ended October 31, 2022. As such, Risk Factors may be updated in annual and quarterly filings. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

Contact:

Kim Duncan

Vice President, Investor Relations and Risk Management

925-460-3663



EN
09/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cooper Companies Inc.

 PRESS RELEASE

CooperCompanies Announces First Quarter 2026 Results

CooperCompanies Announces First Quarter 2026 Results SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026. First quarter 2026 revenue of $1.024 billion, up 6%, or up 3% organically, from last year's first quarter.First quarter 2026 GAAP diluted earnings per share (EPS) of $0.66, up $0.14 or 27% from last year's first quarter.First quarter 2026 Non-GAAP diluted EPS of $1.10, up $0.18 or 20% from last year's first quarter. See "Recon...

 PRESS RELEASE

CooperCompanies Announces Release Date for First Quarter 2026

CooperCompanies Announces Release Date for First Quarter 2026 SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, March 5, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at . About Cooper...

 PRESS RELEASE

CooperCompanies to Present at the J.P. Morgan Healthcare Conference

CooperCompanies to Present at the J.P. Morgan Healthcare Conference SAN RAMON, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will participate at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Al White, President and CEO, will represent the Company in a session scheduled to begin at 5:15pm ET. A live and archived webcast of the event, where applicable, will be available on the CooperCompanies’ website at . About CooperCompaniesCooperCompanies (Nasdaq: COO) is a leading global medical de...

Cooper Companies Inc: 1 director

A director at Cooper Companies Inc bought 1,784 shares at 84.060USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

 PRESS RELEASE

CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Dire...

CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors Enters into Cooperation Agreement with Browning West SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that the Company’s Board of Directors (the “Board”) has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the “Cooperation Agreement”) with Browning West, LP. (“Browning West”). Mr....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch